Impel NeuroPharmaImpel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand.

Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in adults received FDA approval in September 2021 and the company followed the regulatory nod with the pricing of a $45 million offering a week later.

Get the full story at our sister site, Drug Delivery Business News.